enfortumab vedotin

Home
Ligands
enfortumab vedotin

GtoPdb Ligand ID: 10738

Synonyms: ASG-22CE | enfortumab vedotin-ejfv | Padcev®

enfortumab vedotin is an approved drug (FDA (2019), EMA (2022))

Comment: Enfortumab vedotin is an anti-Nectin 4 monoclonal antibody-drug conjugate [3]. The toxic payload is monomethyl auristatin E (MMAE; PubChem CID 11542188). It exhibits potent efficacy in multiple preclinical cancer models [1].

References
1. Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR et al.. (2016) Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res, 76 (10): 3003-13. [PMID:27013195]
2. Hanna KS. (2020) Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma. Drugs, 80 (1): 1-7. [PMID:31823332]
3. McGregor BA, Sonpavde G. (2019) Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma. Expert Opin Investig Drugs, 28 (10): 821-826. [PMID:31526130]

References

1. Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR et al.. (2016)
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Cancer Res, 76 (10): 3003-13. [PMID:27013195]

2. Hanna KS. (2020)
Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Drugs, 80 (1): 1-7. [PMID:31823332]

3. McGregor BA, Sonpavde G. (2019)
Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
Expert Opin Investig Drugs, 28 (10): 821-826. [PMID:31526130]